Company News

New Journey of Listed Gan & Lee

  • Time: 2020-06-30 17:47:00
  • Click Rate: 4116

Beijing, China, June 29, 2020Gan & Lee Pharmaceuticals (hereinafter referred to as “Gan & Lee”) was officially listed on the A-share market in Shanghai Stock Exchange with referred stock certificate “GT”, stoke certificate code “603087”. Gan & Lee has issued 40.2 million shares at a price of 63.32 yuan per share.

Picture: The bell-ringing scene for the listing of Gan & Lee Pharmaceuticals

Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization. The company is mainly engaged in the R&D, production and marketing of recombinant insulin analogues and injections. The product portfolio of Gan & Lee covers all provinces, municipalities and autonomous regions in mainland, China, becoming the leading brand of insulin analogues in China. Since 2005, Gan & Lee has established global business networks in more than 30 countries and regions such as Southeast Asia, Latin America, Middle East & North Africa and Russia, etc. In 2018, Gan & Lee has formally concluded a strategic cooperation agreement with Sandoz, a division of Novartis, an international pharmaceutical giant, for the expansion of the European and American markets.

Picture: Listing ceremony group photo of bell-ringing guests and invited guests at the ceremonial field

Zhao Lei, deputy secretary of Tongzhou District Committee and chief executive of Tongzhou District, Beijing, said, “the listing of Gan & Lee is an important turning point for the development of company. We hope that Gan & Lee can seize the opportunity and take advantage of the capital market to enhance its comprehensive competitiveness, to aspire for a global overall market arrangement, to provide mankind with the highest quality pharmaceuticals and services, to return the community and its investors with outstanding achievements. It is hoped that regulatory authorities, relevant parties and people from all sectors of the community would highly support Gan & Lee to become stronger and stronger”.

Picture: Speech by Mr. Zhao Lei, deputy secretary of Tongzhou District Committee and chief executive of Tongzhou District

Dr. Gan Zhongru, the chairman of Gan & Lee, delivered an important presentation at the listing ceremony and demonstrated, “as an important milestone in the development of Gan & Lee, the successful listing makes the company step into a new phase, and lays a solid foundation for a further huge progress. In the future with the leading advantages of the company's founding team and introduced top talents in the research and development of diabetes treatment, the company plans to develop innovative drugs with fully independent intellectual property rights and enter into the market of developed countries. Meanwhile, the company will increase the sales and marketing of existing products and pioneer the new market by launching new products, further improving the company's profitability and market competitiveness in the field of diabetes treatment”.

Picture: Speech by Dr. Gan Zhongru, chairman of Gan & Lee Pharmaceuticals

The new journey has begun. In the future, Gan & Lee will possess the production capacity of insulin injection, oral hypoglycemic drugs and the products of and beyond diabetes related medical devices, fully cover the three product pipelines in the field of diabetes diagnosis and treatment, and further promote the company's profitability and market competitiveness. The company will also actively invest in tumor disease, chemical medicine, eukaryotic and prokaryotic protein engineering, cardiovascular and metabolic diseases and other research fields, so as to continuously move forward to become a world-class pharmaceutical company and return the whole society and its investors with more high-quality products, more outstanding performance and more excellent brand image.